ArticleCase reports in ophthalmology
Retinal Vasculitis Secondary to Durvalumab.
Article in Case reports in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review.BMC rheumatology · 2025Pooled it
- Current landscape of drug induced retinal vasculitis.Journal of ophthalmic inflammation and infection · 2026Review
- Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review.Biomedicines · 2024Review
- Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.Journal of ophthalmic inflammation and infection · 2023Article
- Ocular Inflammation Induced by Immune Checkpoint Inhibitors.Journal of clinical medicine · 2022Article
- Review
- Case report: Camrelizumab associated with central retinal vein occlusion.Frontiers in immunology · 2022Article
- Ocular Toxicity of Targeted Anticancer Agents.Drugs · 2021Review
- Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.Frontiers in immunology · 2021Review
- Sight-Threatening Immune Retinopathy Developing Secondary to Durvalumab Treatment of Small-Cell Lung Cancer: A Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, the retinal vasculitis resolved and macular edema improved during follow-up. There was no need for durvalumab to be withdrawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.